Prosensa to Present Data at the World Muscle Society Congress

Leiden, The Netherlands, September 8, 2009 – Prosensa, the Dutch based biopharmaceutical company focusing on RNA modulating therapeutics announces two scheduled presentations of data on its lead product candidate, PRO-051, at the 14th International Congress of the World Muscle Society, September 9-12, 2009 in Geneva, Switzerland.

Dr. Judith van Deutekom, PhD, Senior Director Discovery at Prosensa will present an overview of the pre-clinical development of Prosensa’s product portfolio for the treatment of Duchenne muscular dystrophy, including PRO-051.

Prof. Dr. Nathalie M. Goemans, MD, from the Center of Metabolic Diseases, University Hospital Gasthuisberg, Leuven, Belgium, will present the phase I/IIa results of Prosensa’s lead compound PRO-051 in patients with Duchenne muscular dystrophy.

Presentations

• “Making Sense of Duchenne - The Role of Preclinical Development”

  Judith van Deutekom

  Date and time of the session: At the Special Industry Forum: Emerging Therapies for Neuromuscular Diseases on Thursday, September 10 from 19:10 - 19:30 in the auditorium R080

• “A phase I/II study on antisense compound PRO-051 in patients with Duchenne muscular dystrophy”

  N.M. Goemans; G. Buyse; M. Tulinius; J.J.G. Verschuuren; S.J. de Kimpe; J.C.T. van Deutekom

  Date and time of the session: Saturday, September 12 from 14:30 - 15:00 in the auditorium R380

link to this press release